CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 28 target
Drug / intervention
Atezolizumab +1 moredrug
Likely dose
Atezolizumab 1200mgfrom record
Key inclusion· 5
  • ✓Advanced non-squamous NSCLC, Stage IV or recurrent after initial curative intent therapy
  • ✓Adults age 18 or older
  • ✓Prior exposure to at least 1 line of therapy
  • ✓Checkpoint inhibitor exposure in immediately prior line of therapy
Key exclusion· 7
  • ✕Presence of driver mutation susceptible to targeted therapy
  • ✕CTCAE v5 grade 3 or higher toxicity from prior immunotherapy
  • ✕Other active invasive malignancy requiring ongoing therapy
  • ✕Progressing or untreated brain metastases

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04691817
NCT04691817Phase 2RecruitingOn TrackUpdated 5mo ago
CompareCT.gov

A Phase Ib-II Trial of Tocilizumab and Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Abramson Cancer Center at Penn Medicine·interventional·Posted Dec 31, 2020·Updated Jan 7, 2026

In Brief

A Phase 2 clinical trial evaluating Atezolizumab and Tocilizumab for Lung Cancer, Nonsmall Cell. Currently recruiting, targeting 28 participants across 1 site.

Detailed Summary

This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer, Nonsmall Cell
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2Recruiting
2021202220232024202520262027
First PostedDec 31, 2020
Enrollment StartJul 25, 2023
Primary CompletionDec 1, 2026
Study CompletionSep 1, 2027
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 5.5 years agoPrimary completion in 5 months

Interventions

Atezolizumabdrug

1200mg infusion

Tocilizumabdrug

Tocilizumab 6mg/kg or 4mg/kg infusion